Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Frail-Immune
2018-000414-38Phase 2Completed
- Sponsor
- Centre Léon Bérard
- Start
- Oct 2018
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab, carboplatin and paclitaxel in head and neck squamous cell carcinoma (HNSCC), sponsored by Centre Léon Bérard. Primary endpoint: Feasibility. Started Oct 2018; status: completed.
02
Drugs
durvalumabcarboplatinpaclitaxel
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2018-000414-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000414-38.